World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
25643
World Ranking
15590
National Ranking
7854

Mizuki Nishino publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mizuki Nishino sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 333 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mizuki Nishino D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mizuki Nishino sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mizuki Nishino is affiliated with Harvard University in the United States and has a research focus primarily in the field of Medicine, with notable contributions to Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, and Cancer Research.

The scope of their research covers several main topics, including:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Lung Cancer Research Studies
  • Chronic Obstructive Pulmonary Disease (COPD) Research

Among recent notable papers authored or co-authored by Mizuki Nishino are:

  • Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels, 2022, JAMA Oncology
  • Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status, 2021, Journal of Thoracic Oncology
  • Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC, 2020, Clinical Cancer Research
  • Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC, 2023, Cancer Discovery
  • Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer, 2020, Clinical Cancer Research

Frequent co-authors collaborating with Mizuki Nishino include:

  • Mark M. Awad
  • Hiroto Hatabu
  • Biagio Ricciuti
  • Lynette M. Sholl
  • Joao V. Alessi

The researcher has published extensively in key scientific venues, with frequent publications appearing in:

  • Journal of Thoracic Oncology
  • Radiology
  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • American Journal of Respiratory and Critical Care Medicine

Mizuki Nishino has contributed to book publications, including a work published by Springer Nature titled Therapy Response Imaging in Oncology in 2020.

Best Publications

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Monitoring immune-checkpoint blockade: response evaluation and biomarker development

    Mizuki Nishino;Nikhil H. Ramaiya;Hiroto Hatabu;F. Stephen Hodi

  • Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis

    Mizuki Nishino;Anita Giobbie-Hurder;Hiroto Hatabu;Nikhil H. Ramaiya

  • Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities

    George R. Washko;Gary M. Hunninghake;Isis E. Fernandez;Mizuki Nishino

  • Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

    Mizuki Nishino;Anita Giobbie-Hurder;Maria Gargano;Margaret Suda

  • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

    Zhao Chen;Katherine Cheng;Zandra Walton;Yuchuan Wang

  • PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

    Mizuki Nishino;Nikhil H. Ramaiya;Mark M. Awad;Lynette M. Sholl

  • Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know

    Mizuki Nishino;Jyothi P Jagannathan;Nikhil H Ramaiya;Annick D Van den Abbeele

  • MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities

    Gary M. Hunninghake;Hiroto Hatabu;Yuka Okajima;Wei Gao

  • Institutional implementation of clinical tumor profiling on an unselected cancer population

    Lynette M. Sholl;Khanh Do;Priyanka Shivdasani;Ethan Cerami

  • Association Between Interstitial Lung Abnormalities and All-Cause Mortality

    Rachel K. Putman;Hiroto Hatabu;Tetsuro Araki;Gunnar Gudmundsson

  • Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

    Stephanie Cardarella;Atsuko Ogino;Mizuki Nishino;Mohit Butaney

  • Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy

    Nishino M;Sholl Lm;Hodi Fs;Hatabu H

  • Primary Retroperitoneal Neoplasms: CT and MR Imaging Findings with Anatomic and Pathologic Diagnostic Clues

    Mizuki Nishino;Katsumi Hayakawa;Manabu Minami;Akira Yamamoto

  • Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions

    Geoffrey R. Oxnard;Geoffrey R. Oxnard;Peter C. Lo;Mizuki Nishino;Suzanne E. Dahlberg

  • The thymus: a comprehensive review.

    Mizuki Nishino;Simon K. Ashiku;Olivier N. Kocher;Robert L. Thurer

  • Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

    F. Stephen Hodi;Marcus Ballinger;Benjamin Lyons;Jean Charles Soria

  • Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.

    Biagio Ricciuti;Suzanne E Dahlberg;Anika Adeni;Lynette M Sholl

  • Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study.

    Tetsuro Araki;Rachel K. Putman;Hiroto Hatabu;Wei Gao;Wei Gao

  • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

    E.J. Aguilar;B. Ricciuti;J.F. Gainor;K.L. Kehl

Frequent Co-Authors

Hiroto Hatabu
Hiroto Hatabu Brigham and Women's Hospital
Mark M. Awad
Mark M. Awad Harvard University
Lynette M. Sholl
Lynette M. Sholl Brigham and Women's Hospital
Pasi A. Jänne
Pasi A. Jänne Harvard University
Bruce E. Johnson
Bruce E. Johnson Harvard University
George R. Washko
George R. Washko Brigham and Women's Hospital
F. Stephen Hodi
F. Stephen Hodi Harvard University
Josée Dupuis
Josée Dupuis McGill University
George T. O'Connor
George T. O'Connor Boston University
Andrew D. Cherniack
Andrew D. Cherniack Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online healthcare education is a smart option for prospective medical students or those interested in related fields. Accredited online programs offer flexibility and accessibility for those balancing work or other commitments. For instance, the best medical billing and coding schools online provide training for in-demand administrative roles in healthcare and often offer financial aid.

Nursing remains a popular career pathway, and you can get started without standardized exam barriers. Programs such as lpn school without teas test let aspiring nurses begin their journey more easily. If you aim to move into leadership or administrative roles, earning a degree from an online healthcare administration degree program can accelerate your progress.

For registered nurses looking to advance, options like adn to fnp bridge programs offer a streamlined pathway to advanced practice and higher earning potential. With so many online opportunities, there’s a flexible route to fit your career goals within healthcare.

Best Scientists Citing Mizuki Nishino

Trending Scientists

Recently Published Articles